Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies

Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung

Clin Mol Hepatol. 2022;28(4):931-932. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0259

View: 2958 Download: 102 Web of Science: 7 Crossref: 6

Original Article

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 5358 Download: 186 Web of Science: 29 Crossref: 32

The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2022;28(4):814-826. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0099

View: 4835 Download: 195 Web of Science: 14 Crossref: 15

Review

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(4):725-738. Published online March 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0015

View: 5057 Download: 252 Web of Science: 7 Crossref: 13

Original Article

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574. Published online May 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0096

View: 6898 Download: 199 Web of Science: 45 Crossref: 48

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients

Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):553-564. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0082

View: 3514 Download: 90 Web of Science: 11 Crossref: 12

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(3):510-521. Published online March 17, 2022

DOI: https://doi.org/10.3350/cmh.2021.0332

View: 6516 Download: 291 Web of Science: 31 Crossref: 26

Editorial

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097

View: 2877 Download: 75 Web of Science: 1 Crossref: 2

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 5109 Download: 335 Web of Science: 7 Crossref: 8

Original Article

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae

Clin Mol Hepatol. 2022;28(2):196-206. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0371

View: 5725 Download: 208 Web of Science: 15 Crossref: 15

Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients

Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng

Clin Mol Hepatol. 2022;28(2):183-195. Published online November 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0301

View: 5860 Download: 213 Web of Science: 5 Crossref: 5

U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases

Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2022;28(1):77-90. Published online November 5, 2021

DOI: https://doi.org/10.3350/cmh.2021.0188

View: 5906 Download: 144 Web of Science: 16 Crossref: 15

Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes

Hydar El Jamaly, Guy D Eslick, Martin Weltman

Clin Mol Hepatol. 2022;28(1):52-66. Published online September 17, 2021

DOI: https://doi.org/10.3350/cmh.2021.0205

View: 6922 Download: 222 Web of Science: 11 Crossref: 13

Editorial

Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment

Ja-Young Kwon

Clin Mol Hepatol. 2022;28(1):50-51. Published online November 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0359

View: 3953 Download: 97

An analysis of polygenic risk scores for non-alcoholic fatty liver disease

Dae Won Jun

Clin Mol Hepatol. 2021;27(3):446-447. Published online May 21, 2021

DOI: https://doi.org/10.3350/cmh.2021.0133

View: 4449 Download: 155 Web of Science: 5 Crossref: 5

Guideline

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho

Clin Mol Hepatol. 2021;27(3):363-401. Published online June 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0178

View: 18228 Download: 1,226 Web of Science: 147 Crossref: 158

Review

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?

Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee

Clin Mol Hepatol. 2021;27(2):257-269. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0067

View: 8872 Download: 432 Web of Science: 64 Crossref: 64

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0239

View: 8404 Download: 362 Web of Science: 27 Crossref: 31

The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease

Erica Jennison, Christopher D. Byrne

Clin Mol Hepatol. 2021;27(1):22-43. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0129

View: 9561 Download: 429 Web of Science: 49 Crossref: 51

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0202

View: 6560 Download: 190 Web of Science: 27 Crossref: 26

Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases

Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2020;26(4):715-727. Published online September 22, 2020

DOI: https://doi.org/10.3350/cmh.2020.0173

View: 9674 Download: 272 Web of Science: 31 Crossref: 32

The effect of moderate alcohol drinking in nonalcoholic fatty liver disease

Jong Hwa Choi, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2020;26(4):662-669. Published online September 25, 2020

DOI: https://doi.org/10.3350/cmh.2020.0163

View: 8922 Download: 168 Web of Science: 37 Crossref: 37

Letter to the Editor

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Dimitrios Patoulias, Michael Doumas

Clin Mol Hepatol. 2020;26(4):582-583. Published online September 25, 2020

DOI: https://doi.org/10.3350/cmh.2020.0264

View: 3620 Download: 67 Web of Science: 2 Crossref: 2

Review

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 10066 Download: 479 Web of Science: 37 Crossref: 38

Original Article

Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease

Nadia Soledad Alegre, Cecilia Claudia Garcia, Luis Ariel Billordo, Beatriz Ameigeiras, Daniel Poncino, Javier Benavides, Luis Colombato, Alejandra Claudia Cherñavsky

Clin Mol Hepatol. 2020;26(2):216-226. Published online December 5, 2019

DOI: https://doi.org/10.3350/cmh.2019.0074

View: 6886 Download: 141 Web of Science: 15 Crossref: 15

Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim

Clin Mol Hepatol. 2020;26(2):209-215. Published online November 4, 2019

DOI: https://doi.org/10.3350/cmh.2019.0065

View: 34203 Download: 408 Web of Science: 77 Crossref: 82

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma

Rahul Kumar, Boon-Bee George Goh, Jia-Wen Kam, Pik-Eu Chang, Chee-Kiat Tan

Clin Mol Hepatol. 2020;26(2):196-208. Published online January 9, 2020

DOI: https://doi.org/10.3350/cmh.2019.0012

View: 8344 Download: 273 Web of Science: 14 Crossref: 16

Editorial

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?

Soung Won Jeong

Clin Mol Hepatol. 2020;26(2):185-186. Published online March 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0046

View: 4561 Download: 89 Web of Science: 1 Crossref: 2

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?

Ju Hyun Shim

Clin Mol Hepatol. 2020;26(2):183-184. Published online March 12, 2020

DOI: https://doi.org/10.3350/cmh.2020.0042

View: 4379 Download: 113 Web of Science: 6 Crossref: 6

Original Article

Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes

Ebrahim Banitalebi, Mohammad Faramarzi, Samira Nasiri, Majid Mardaniyan, Vahid Rabiee

Clin Mol Hepatol. 2019;25(3):294-304. Published online May 30, 2019

DOI: https://doi.org/10.3350/cmh.2018.0086

View: 7282 Download: 258 Web of Science: 13 Crossref: 17

1 | 2 | 3 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5413	MAFLD: How is it different from NAFLD?
Viewed By 5222	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5101	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search